All In Biotech

Free tool

FAERS Monitor: Evomela

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 207155 or its brand name (Evomela, Melphalan Hydrochloride). Reports on generic versions are filed under their own applications.

Reports

22,969

Serious

22,377

97% of reports

Hospitalization

6,655

Death reported

5,247

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • off label use2,484
  • drug ineffective1,400
  • plasma cell myeloma1,286
  • febrile neutropenia1,255
  • mucosal inflammation1,148
  • neutropenia1,124
  • pyrexia1,071
  • pneumonia1,066
  • thrombocytopenia1,048
  • diarrhoea1,016
  • product use in unapproved indication929
  • sepsis809
  • disease progression782
  • infection718
  • neuropathy peripheral699

Reports by year received

View as table
YearReports
2004156
2005324
2006216
2007211
2008320
2009369
2010181
2011531
2012458
2013772
2014898
20151,161
20161,184
20171,236
20181,681
20191,868
20201,937
20211,961
20221,538
20231,964
20241,736
20251,262
20261,005

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,031,190 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
mucosal inflammationSignal1,14841.939.643,892
plasma cell myelomaSignal1,28631.229.536,364
febrile neutropeniaSignal1,25517.616.719,371
thrombocytopeniaSignal1,0488.78.27,057
neutropeniaSignal1,1247.67.26,451
neuropathy peripheralSignal6996.86.33,423
sepsisSignal8096.76.23,896
disease progressionSignal7826.15.73,315
infectionSignal7184.64.21,996
product use in unapproved indicationSignal9293.43.21,620
pneumoniaSignal1,0663.02.81,458
pyrexiaSignal1,0712.82.71,292
off label useSignal2,4842.62.52,548
diarrhoea1,0161.41.4141
drug ineffective1,4001.00.91

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.